Source: Acrofan

MiNA: MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual Ameri

Read full article »
MiNA's Competitors | MiNA's News | MiNA's Financials
Stay up-to-date with the latest news on MiNA
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
Robert Habib's photo - CEO of MiNA

CEO

Robert Habib

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on MiNA